Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

311 - 320of 392 News

December 05, 2018

Capital Markets Day 2018

Bayer to drive value creation as company pursues ambitious growth targets through 2022

November 29, 2018

Group to take comprehensive range of portfolio, efficiency and structural measures

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

November 27, 2018

Not intended for U.S. and UK Media

Bayer receives EU approval for its hemophilia A treatment Jivi®

November 27, 2018

Not intended for U.S. and UK Media

U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion

November 13, 2018

Third quarter of 2018

Bayer: Good performance in a challenging environment, Group outlook confirmed

October 24, 2018

Not intended for U.S. and UK Media

Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint

October 21, 2018

Not intended for U.S. and UK Media - ESMO 2018 Congress (European Society for Medical Oncology)

Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types

October 12, 2018

Not intended for U.S. and UK Media

U.S. FDA approves Bayer’s Xarelto® for patients with coronary or peripheral artery disease

September 21, 2018

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027

September 21, 2018

Not intended for U.S. and UK Media

Bayer’s Jivi® approved in Japan for hemophilia A

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk